Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1291175 | 0.98 | MEN1 (0.50) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL1447319 | 0.88 | KEAP1 (0.55) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL20762021 | 0.86 | KEAP1 (0.53) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL1830508 | 0.84 | SMN1; SMN2 (0.52) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL2183875 | 0.84 | SMN1; SMN2 (0.52) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL28572354 | 0.82 | MEN1 (0.55) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL3218443 | 0.79 | L3MBTL1 (0.41) | KMT2ACA2CA1HRH3ALDH1A1 | |
| SCHEMBL13974361 | 0.79 | HRH3 (0.37) | CA2CA1HRH3ALDH1A1 | |
| SCHEMBL426047 | 0.78 | KMT2A (0.51) | MEN1KMT2AKEAP1SMN1; SMN2CA2 | |
| SCHEMBL4974769 | 0.78 | MEN1 (0.51) | MEN1KMT2AKEAP1SMN1; SMN2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | claimed |
| EP-3955923-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | The Regents Of The University Of Michigan (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2020215037-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-22 | — | — | WO | claimed |
| EP-1492536-B1 | 4-(N-PHENYLAMINO)-QUINAZOLINES / QUINOLINES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-05-09 | — | — | EP | claimed |
| US-7119084-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-10 | — | — | US | claimed |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-6924285-B2 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. (DE) | 2005-08-02 | — | — | US | claimed |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-11 | — | — | US | claimed |
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | TENAYA THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-30 | — | — | US | disclosed |
| US-6100258-A | 6-(N-(5-BROMO-2-(2-METHYLPROP-2-EN-1-YLOXY)BENZYL)-N -ETHYLAMINO)-PYRIDAZIN-3-YLCARBOXYLIC ACID, AND OTHER 3,6-DISUBSTITUTED PYRIDAZINE DERIVATIVES OF SPECIFIED FORMULA; RELIEVING PAIN | ZENECA LIMITED (GB) | 2000-08-08 | — | — | US | disclosed |
| WO-2000044716-A1 | ACETYLENIC SULFONAMIDE THIOL TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000024710-A1 | N-(2-ARYL-PROPIONYL)-SULFONAMIDES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | DOMPE' S.P.A. (IT) | 2000-05-04 | — | — | WO | disclosed |
| CN-1193966-A | Aromatic compounds and pharmaceutical compositions containing them | ZENECA LTD (GB) | 1998-09-23 | — | — | CN | disclosed |
| EP-0847391-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-06-17 | — | — | EP | disclosed |
| WO-1997000864-A1 | AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269137-A1 | HDAC6 INHIBITORS FOR TREATMENT OF DILATED CARDIOMYOPATHY | HDAC6, HDAC1, HDAC2 | MEN1 4238/4885KMT2A 565/4885KEAP1 591/4885 |
| US-11607414-B2 | Small molecule inhibitors of EGFR and PI3K | EGFR, ERBB2, ERBB3 | MEN1 1984/4885KMT2A 2786/4885KEAP1 1645/4885 |
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | MEN1 3206/4885KMT2A 3406/4885KEAP1 1060/4885 |
| US-20220202818-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | CD274, PDCD1, PDCD1LG2 | MEN1 342/4885KMT2A 914/4885KEAP1 184/4885 |
| US-20050182043-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B2, CYP11B1, HPGD | MEN1 916/4885KMT2A 4215/4885KEAP1 206/4885 |
| US-20040048880-A1 | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them | CYP11B1, AR, CYP11B2 | MEN1 1913/4885KMT2A 4308/4885KEAP1 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.